当前位置： SCI文献检索 > ALIMENTARY PHARMACOLOGY & THERAPEUTICS期刊下所有文献 > A randomized comparative study of esomeprazole 40 mg versus pantoprazole 40 mg for healing erosive oesophagitis: the EXPO study.

A randomized comparative study of esomeprazole 40 mg versus pantoprazole 40 mg for healing erosive oesophagitis: the EXPO study.

Abstract：

AIM:To assess the efficacy of the 8-week therapy with esomeprazole 40 mg vs. pantoprazole 40 mg for healing erosive oesophagitis (EE) as part of a management study. METHODS:Patients had a history of gastro-oesophageal reflux disease symptoms (> or =6 months) and had suffered heartburn on at least 4 of the 7 days preceding enrollment. Endoscopies were performed to grade EE severity using the Los Angeles (LA) classification system at baseline, 4 and 8 weeks (if unhealed at 4 weeks). Heartburn severity was recorded by patients on diary cards. The primary end point was healing of EE by week 8 of treatment. RESULTS:Of 3170 patients randomized, the intent-to-treat population consisted of 3151 patients (63% male, mean age: 50.6 years, 27% Helicobacter pylori-positive). Esomeprazole 40 mg healed a significantly greater proportion of EE patients than pantoprazole 40 mg at both 4 weeks (life table estimates: esomeprazole 81%, pantoprazole 75%, P < 0.001) and 8 weeks (life table estimates: esomeprazole 96%, pantoprazole 92%, P < 0.001). The median time to reach sustained heartburn resolution was 6 days in patients receiving esomeprazole and 8 days with pantoprazole (P < 0.001). CONCLUSION:Esomeprazole 40 mg is more effective than pantoprazole 40 mg for healing EE and providing resolution of associated heartburn.

journal_name

Aliment Pharmacol Ther

journal_title

Alimentary pharmacology & therapeutics

authors

Labenz J,Armstrong D,Lauritsen K,Katelaris P,Schmidt S,Schütze K,Wallner G,Juergens H,Preiksaitis H,Keeling N,Nauclér E,Eklund S,Expo Study Investigators.

doi

10.1111/j.1365-2036.2005.02368.x

subject

Has Abstract

pub_date

2005-03-15 00:00:00

pages

739-46

issue

6

eissn

0269-2813

issn

1365-2036

pii

APT2368

journal_volume

21

pub_type

临床试验,杂志文章,多中心研究,随机对照试验

相关文献

ALIMENTARY PHARMACOLOGY & THERAPEUTICS文献大全
  • Comparison of one-day oral dosing with three bismuth compounds for the suppression of Helicobacter pylori assessed by the 13C-urea breath test.

    abstract：:Assessment of intragastric urease activity by the 13C-urea breath test was performed before and after one day of dosing with either De-Noltabs (tripotassium dicitrato bismuthate, one tablet 1 q.d.s.), Pepto-Bismol liquid (bismuth salicylate 30 ml q.d.s.), or Roter tablets (bismuth subnitrate, one tablet q.d.s.) in twe...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章

    doi：10.1111/j.1365-2036.1992.tb00549.x

    authors： Prewett EJ,Luk YW,Fraser AG,Lam WM,Pounder RE

    更新日期：1992-02-01 00:00:00

  • An open trial of long-term therapy with lansoprazole in patients with peptic ulceration resistant to extended high-dose ranitidine treatment.

    abstract：:Forty-two patients with peptic ulceration of the duodenum, stomach or oesophagus, who had not responded to 3 or more months of high-dose treatment with ranitidine (450 or 600 mg/day), were treated with oral lansoprazole at 30-60 mg daily. In 40 patients (95.2%) the ulcers healed within 2-12 weeks. In the remaining 2 p...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 临床试验,杂志文章

    doi：10.1111/j.1365-2036.1993.tb00589.x

    authors： Brunner G,Arnold R,Hennig U,Fuchs W

    更新日期：1993-01-01 00:00:00

  • Review article: gastric electrical stimulation for gastroparesis--physiological foundations, technical aspects and clinical implications.

    abstract：BACKGROUND:Application of electrical stimulation to the gut, primarily the stomach, has rapidly advanced in the last two decades, from mostly animal studies to the clinical arena. Most studies focused on the use of electrical stimulation for gastroparesis, the only approved indication for such intervention. AIM:To rev...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章,评审

    doi：10.1111/j.1365-2036.2009.04082.x

    authors： Soffer E,Abell T,Lin Z,Lorincz A,McCallum R,Parkman H,Policker S,Ordog T

    更新日期：2009-10-01 00:00:00

  • Review article: current management of renal dysfunction in the cirrhotic patient.

    abstract：:The United Network for Organ Sharing database revealed that over the last 4-5 years, an average of 1800 patients were removed from the cadaveric waiting list annually because of patients' death and an additional 400-500 were removed from the list because of the severity of their illnesses. The pre-transplant evaluatio...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章,评审

    doi：10.1111/j.1365-2036.2005.02357.x

    authors： Pham PT,Pham PC,Rastogi A,Wilkinson AH

    更新日期：2005-04-15 00:00:00

  • Comparison of the effects of intravenously and orally administered esomeprazole on acid output in patients with symptoms of gastro-oesophageal reflux disease.

    abstract：BACKGROUND:Intravenous esomeprazole may be beneficial for patients who cannot take oral medications. AIM:To compare intravenous esomeprazole with oral esomeprazole for effects on maximal acid output during pentagastrin stimulation in patients with gastro-oesophageal reflux disease symptoms. METHODS:In four separate o...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章,多中心研究,随机对照试验

    doi：10.1111/j.1365-2036.2005.02659.x

    authors： Metz DC,Miner PB,Heuman DM,Chen Y,Sostek M

    更新日期：2005-11-01 00:00:00

  • Incidence, clinical presentation and mortality of liver cirrhosis in Southern Sweden: a 10-year population-based study.

    abstract：BACKGROUND:In Sweden, the most common causes of liver cirrhosis are alcohol overconsumption and hepatitis C. However, recent data on the clinical characteristics of Swedish patients with cirrhosis are scarce. AIMS:To determine the incidence, clinical presentation, aetiological spectrum and survival rates of liver cirr...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章

    doi：10.1111/apt.13635

    authors： Nilsson E,Anderson H,Sargenti K,Lindgren S,Prytz H

    更新日期：2016-06-01 00:00:00

  • How accurate is the determination of blood in gastric juice? Comparison of peroxidase and porphyrin methods.

    abstract：BACKGROUND:Mucosal bleeding is frequently used as a measure of gastric mucosal integrity. We compared the orthotolidine method for quantifying haemoglobin in gastric juice with a method based on measurement of fluorescent porphyrins extracted from haem. We also investigated whether acid or pepsin had a deleterious effe...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章

    doi：10.1111/j.0953-0673.1996.00333.x

    authors： Woods KL,Kiefe C,Graham DY

    更新日期：1996-06-01 00:00:00

  • Gastric carcinoids after long-term use of a proton pump inhibitor.

    abstract：BACKGROUND:Proton pump inhibitors (PPIs) are potent inhibitors of gastric acid secretion and give hypergastrinemia secondary to gastric hypoacidity. PPI treatment therefore induces enterochromaffin-like (ECL) cell hyperplasia. Long-term hypergastrinemia in rodents and man also leads to ECL cell neoplasia. Whether long-...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章

    doi：10.1111/apt.12012

    authors： Jianu CS,Fossmark R,Viset T,Qvigstad G,Sørdal O,Mårvik R,Waldum HL

    更新日期：2012-10-01 00:00:00

  • Occurrence and risk factors for benign epithelial gastric polyps in atrophic body gastritis on diagnosis and follow-up.

    abstract：BACKGROUND:Benign epithelial gastric polyps have been reported to be more common in atrophic body gastritis. The role of Helicobacter pylori infection in the induction of gastric atrophy is well-known. The development of hyperplastic polyps may be in relation to H. pylori infection. AIM:To investigate occurrence of be...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章

    doi：10.1111/j.1365-2036.2005.02399.x

    authors： Di Giulio E,Lahner E,Micheletti A,Milione M,D'Ambra G,Bordi C,Delle Fave G,Annibale B

    更新日期：2005-03-01 00:00:00

  • 5-day vs. 7-day triple therapy with rabeprazole, clarithromycin and amoxicillin for Helicobacter pylori eradication.

    abstract：AIM:To determine whether a 5-day regimen with rabeprazole, clarithromycin and amoxicillin (RCA) was as effective as a 7-day regimen. METHODS:A total of 139 H. pylori-infected patients were randomized to receive either a 5-day or 7-day course of rabeprazole 10 mg b.d., clarithromycin 400 mg b.d. and amoxicillin 750 mg ...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 临床试验,杂志文章,随机对照试验

    doi：10.1046/j.1365-2036.2000.00892.x

    authors： Isomoto H,Furusu H,Morikawa T,Mizuta Y,Nishiyama T,Omagari K,Murase K,Inoue K,Murata I,Kohno S

    更新日期：2000-12-01 00:00:00

  • Association between diabetes mellitus and hepatic encephalopathy in patients with cirrhosis.

    abstract：BACKGROUND:Diabetes mellitus may lead to increased serum ammonia and systemic inflammation thereby promoting hepatic encephalopathy (HE). AIM:To investigate the potential association between diabetes mellitus/glycaemic control and the presence of covert HE as well as the development of overt HE in a prospective settin...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章

    doi：10.1111/apt.15915

    authors： Labenz C,Nagel M,Kremer WM,Hilscher M,Schilling CA,Toenges G,Kuchen R,Schattenberg JM,Galle PR,Wörns MA

    更新日期：2020-08-01 00:00:00

  • Review article: liver support systems in acute hepatic failure.

    abstract：:The treatment of acute hepatic failure has developed rapidly over the last 40 years, reducing morbidity and mortality from this syndrome. Whilst this has been partly attributed to significant improvements in the specialist medical management of these patients, advances in surgical techniques and pharmaceutical develop...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章,评审

    doi：10.1046/j.1365-2036.1999.00597.x

    authors： Rahman TM,Hodgson HJ

    更新日期：1999-10-01 00:00:00

  • Efficacy of proton pump inhibitor therapy for eosinophilic oesophagitis in 630 patients: results from the EoE connect registry.

    abstract：BACKGROUND:Proton pump inhibitors (PPIs) are the most commonly used first-line therapy for patients with eosinophilic oesophagitis (EoE). However, many aspects related to PPIs in EoE are still unknown. AIMS:To assess the effectiveness of PPI therapy for EoE in real-world practice. METHODS:This cross-sectional study c...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章

    doi：10.1111/apt.15957

    authors： Laserna-Mendieta EJ,Casabona S,Guagnozzi D,Savarino E,Perelló A,Guardiola-Arévalo A,Barrio J,Pérez-Martínez I,Lund Krarup A,Alcedo J,de la Riva S,Rey-Iborra E,Santander C,Arias Á,Lucendo AJ,EUREOS EoE CONNECT Research group

    更新日期：2020-09-01 00:00:00

  • Characteristics of patients with irritable bowel syndrome recruited from three sources: implications for clinical trials.

    abstract：BACKGROUND:Variation in the characteristics of irritable bowel syndrome patients recruited for clinical trials from different sources could affect their response and the generalizability of trial results. AIM:To describe and compare the characteristics of three different groups of irritable bowel syndrome patients rec...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章

    doi：10.1046/j.1365-2036.2001.01010.x

    authors： Longstreth GF,Hawkey CJ,Mayer EA,Jones RH,Naesdal J,Wilson IK,Peacock RA,Wiklund IK

    更新日期：2001-07-01 00:00:00

  • Effects of baseline abdominal pain and bloating on response to lubiprostone in patients with irritable bowel syndrome with constipation.

    abstract：BACKGROUND:Lubiprostone (8 μg b.d.) received US Food and Drug Administration (FDA) approval in 2008 for the treatment of constipation-predominant irritable bowel syndrome (IBS-C) in women aged ≥18 years. In 2012, the FDA issued new guidance for IBS-C clinical trials, recommending a composite endpoint incorporating both...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章,随机对照试验

    doi：10.1111/apt.13807

    authors： Chang L,Chey WD,Drossman D,Losch-Beridon T,Wang M,Lichtlen P,Mareya S

    更新日期：2016-11-01 00:00:00

  • Randomised clinical trial: a herbal preparation of myrrh, chamomile and coffee charcoal compared with mesalazine in maintaining remission in ulcerative colitis--a double-blind, double-dummy study.

    abstract：BACKGROUND:The herbal treatment with myrrh, dry extract of chamomile flowers and coffee charcoal has anti-inflammatory and antidiarrhoeal potential and might benefit patients with UC. Aminosalicylates are used as standard treatment for maintaining remission in ulcerative colitis (UC). AIM:To compare the efficacy of th...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章,随机对照试验

    doi：10.1111/apt.12397

    authors： Langhorst J,Varnhagen I,Schneider SB,Albrecht U,Rueffer A,Stange R,Michalsen A,Dobos GJ

    更新日期：2013-09-01 00:00:00

  • Symptomatic and endoscopic duodenal ulcer relapse rates 12 months following Helicobacter pylori eradication treatment with omeprazole and amoxycillin with or without metronidazole.

    abstract：AIM:To determine the effect of Helicobacter pylori eradication with omeprazole and amoxycillin, with or without metronidazole, on the 12-month course of duodenal ulcer disease. METHODS:In a randomized; double-blind study, conducted in 19 hospitals, 105 H. pylori positive duodenal ulcer patients were healed and symptom...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 临床试验,杂志文章,随机对照试验

    doi：10.1046/j.1365-2036.1996.36178000.x

    authors： Bell GD,Bate CM,Axon AT,Tildesley G,Martin JL,Taylor MD,Richardson PD

    更新日期：1996-08-01 00:00:00

  • Randomised clinical trial: safety, efficacy and pharmacokinetics of HS-10234 versus tenofovir for the treatment of chronic hepatitis B infection.

    abstract：BACKGROUND:HS-10234 is a novel prodrug of tenofovir developed to increase anti-viral potency and to reduce systemic toxicities. AIMS:To evaluate the tolerability, pharmacokinetics and anti-viral efficacy of HS-10234 in patients with chronic hepatitis B (CHB) infection METHODS: Treatment-naïve subjects with non-cirrhot...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章

    doi：10.1111/apt.16196

    authors： Zhang H,Hu Y,Wu M,Liu J,Zhu X,Li X,Chen H,Li C,Liu C,Niu J,Ding Y

    更新日期：2021-01-01 00:00:00

  • A 6-month, open-label clinical trial of pancrelipase delayed-release capsules (Creon) in patients with exocrine pancreatic insufficiency due to chronic pancreatitis or pancreatic surgery.

    abstract：BACKGROUND:Pancreatic enzyme replacement therapy (PERT) is necessary to prevent severe maldigestion and unwanted weight loss associated with exocrine pancreatic insufficiency (EPI) due to chronic pancreatitis (CP) or pancreatic surgery (PS). AIM:To assess the long-term safety and efficacy of pancrelipase (pancreatin) ...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章,多中心研究,随机对照试验

    doi：10.1111/j.1365-2036.2011.04631.x

    authors： Gubergrits N,Malecka-Panas E,Lehman GA,Vasileva G,Shen Y,Sander-Struckmeier S,Caras S,Whitcomb DC

    更新日期：2011-05-01 00:00:00

  • The safety profile of anti-tumour necrosis factor therapy in inflammatory bowel disease in clinical practice: analysis of 620 patient-years follow-up.

    abstract：BACKGROUND:Anti-TNF agents are now widely used in Crohn's disease (CD), and in ulcerative colitis (UC). AIM:To review the safety profile of anti-TNF agents in all patients treated with infliximab in Edinburgh from 1999 to 2007. METHODS:Complete data were available on 202/207 patients comprising 157 CD, 42 UC and thre...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章

    doi：10.1111/j.1365-2036.2008.03882.x

    authors： Lees CW,Ali AI,Thompson AI,Ho GT,Forsythe RO,Marquez L,Cochrane CJ,Aitken S,Fennell J,Rogers P,Shand AG,Penman ID,Palmer KR,Wilson DC,Arnott ID,Satsangi J

    更新日期：2009-02-01 00:00:00

  • Review article: proton pump inhibitors with clopidogrel--evidence for and against a clinically-important interaction.

    abstract：BACKGROUND:The treatment of acute coronary syndromes involves a combination of antiplatelet therapies. Proton pump inhibitors are frequently recommended for patients receiving clopidogrel in addition to aspirin, to minimise the risk of bleeding. Several studies have shown that proton pump inhibitors can affect the plat...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章,评审

    doi：10.1111/j.1365-2036.2011.04585.x

    authors： Disney BR,Watson RD,Blann AD,Lip GY,Anderson MR

    更新日期：2011-04-01 00:00:00

  • Two mesalazine regimens in the prevention of the post-operative recurrence of Crohn's disease: a pragmatic, double-blind, randomized controlled trial.

    abstract：BACKGROUND:The role of mesalazine in preventing the clinical recurrence of Crohn's disease after surgery has been shown in a meta-analysis of all published studies. No clear relationship, however, has been shown between dosage and response. AIM:To evaluate whether 4.0 g/day of mesalazine may offer therapeutic advantag...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 临床试验,杂志文章,多中心研究,随机对照试验

    doi：10.1046/j.1365-2036.2003.01462.x

    authors： Caprilli R,Cottone M,Tonelli F,Sturniolo G,Castiglione F,Annese V,Papi C,Viscido A,Cammà C,Corrao G,Latella G

    更新日期：2003-02-15 00:00:00

  • The effect of portal hypertension on indomethacin-induced small intestinal ulceration in the rat.

    abstract：:The purpose of this study was to determine whether portal hypertension potentiates intestinal ulceration induced by indomethacin. Portal hypertension was produced in male Sprague-Dawley rats by two-staged ligation of the portal vein. Sham-operated rats were used as controls. The rats were given 20 mg/kg of indomethaci...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章

    doi：10.1111/j.1365-2036.1991.tb00004.x

    authors： Jonas GM,Erickson RA,Chung K

    更新日期：1991-02-01 00:00:00

  • Intravenous and oral lansoprazole are equivalent in suppressing stimulated acid output in patient volunteers with erosive oesophagitis.

    abstract：BACKGROUND:Some patients requiring acid suppression may be unable to take oral medications. AIM:To compare the gastric acid inhibition effects of lansoprazole 30 mg administered either intravenous or orally in erosive oesophagitis patients. METHODS:The study included 87 Helicobacter pylori-negative patients with eros...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 临床试验,杂志文章,多中心研究,随机对照试验

    doi：10.1111/j.1365-2036.2004.02188.x

    authors： Kovacs TO,Lee CQ,Chiu YL,Pilmer BL,Metz DC

    更新日期：2004-10-15 00:00:00

  • Rifaximin in the treatment of recurrent Clostridium difficile infection.

    abstract：BACKGROUND:Clostridium difficile can cause severe antibiotic-associated colitis. Conventional treatments with metronidazole and vancomycin improve symptoms, but after discontinuation of treatment, C. difficile infection (CDI) recurs in a number of patients. Rifaximin is a rifamycin-based non-systemic antibiotic that ha...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章

    doi：10.1111/apt.12111

    authors： Mattila E,Arkkila P,Mattila PS,Tarkka E,Tissari P,Anttila VJ

    更新日期：2013-01-01 00:00:00

  • Systematic review: herbal medicinal products for non-ulcer dyspepsia.

    abstract：BACKGROUND:Non-ulcer dyspepsia is predominantly a self-managed condition, although it accounts for a significant number of general practitioner consultations and hospital referrals. Herbal medicinal products are often used for the relief of dyspeptic symptoms. AIMS:: To critically assess the evidence for and against h...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章,评审

    doi：10.1046/j.1365-2036.2002.01339.x

    authors： Thompson Coon J,Ernst E

    更新日期：2002-10-01 00:00:00

  • Atrophic gastritis during long-term omeprazole therapy affects serum vitamin B12 levels.

    abstract：BACKGROUND:Omeprazole maintenance therapy for gastro-oesophageal reflux disease (GERD) has been associated with an increased incidence of atrophic gastritis in H. pylori-infected patients and with a decreased absorption of protein-bound, but not of unbound cobalamin. AIM:: To test the hypothesis that the combination o...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章

    doi：10.1046/j.1365-2036.1999.00616.x

    authors： Schenk BE,Kuipers EJ,Klinkenberg-Knol EC,Bloemena EC,Sandell M,Nelis GF,Snel P,Festen HP,Meuwissen SG

    更新日期：1999-10-01 00:00:00

  • Persistent small bowel mucosal villous atrophy without symptoms in coeliac disease.

    abstract：BACKGROUND:Refractory sprue with malabsorption carries a risk of lymphoma. AIM:To examine whether a good clinical but poor histological response during a strict gluten-free diet predicts a poor outcome. METHODS:The study involved all coeliac patients who showed no histological recovery within 2 years on a strict glut...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章,随机对照试验

    doi：10.1111/j.1365-2036.2007.03311.x

    authors： Kaukinen K,Peräaho M,Lindfors K,Partanen J,Woolley N,Pikkarainen P,Karvonen AL,Laasanen T,Sievänen H,Mäki M,Collin P

    更新日期：2007-05-15 00:00:00

  • Patterns and predictors of mortality and disease progression among patients with non-alcoholic fatty liver disease.

    abstract：BACKGROUND:Factors associated with mortality and disease progression in non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) are poorly understood. AIMS:To assess the impact of liver disease severity, demographics and comorbidities on all-cause mortality and liver disease progression in a...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章

    doi：10.1111/apt.16016

    authors： Canbay A,Kachru N,Haas JS,Sowa JP,Meise D,Ozbay AB

    更新日期：2020-10-01 00:00:00

  • Systematic review: quality of trials on the symptomatic effects of the low FODMAP diet for irritable bowel syndrome.

    abstract：BACKGROUND:The low Fermentable Oligo-, Di- Monosaccharides, and Polyoles (FODMAP) diet is a new treatment option for irritable bowel syndrome (IBS). Experts refer to the diet as supported by high level of evidence, but an evaluation of the quality of trials is lacking. AIM:To provide a systematic review of the quality...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章,评审

    doi：10.1111/apt.14065

    authors： Krogsgaard LR,Lyngesen M,Bytzer P

    更新日期：2017-06-01 00:00:00